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Congenital lipoid adrenal hyperplasia (CLAH) is caused by mutations to the ste-
roidogenic acute regulatory protein (StAR) gene associated with the inability to 
synthesize all adrenal and gonadal steroids. Inadequate treatment in an infant with 
this condition may result in sudden death from an adrenal crisis. We report a case 
in which CLAH developed in Korean siblings; the second child was prenatally di-
agnosed because the first child was affected and low maternal serum estriol was 
detected in a prenatal screening test. To our knowledge, this is the first prenatal di-
agnosis of the Q258X StAR mutation, which is the only consistent genetic cluster 
identified to date in Japanese and Korean populations. 
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INTRODUCTION
Congenital lipoid adrenal hyperplasia (CLAH) is the most severe form of congeni-
tal adrenal hyperplasia in which the synthesis of all adrenal and gonadal steroid 
hormones is impaired, due to mutations to the steroidogenic acute regulatory pro-
tein (StAR) gene.1 Clinical findings in these patients are salt loss, hypoglycemia, 
pigmentation and male sex reversal. Delay in treatment may result in sudden death 
from adrenal crisis. While the homozygous c.201-202 delCT StAR mutation has 
been prenatally diagnosed in Palestinians, this is the first prenatal diagnosis of the 
Q258X StAR mutation, which is the only consistent genetic cluster identified to 
date in Japanese and Korean populations.2-7
 
CASE REPORT
 
A 33-year-old G2P1 woman presented to our obstetric unit at 17 weeks’ gestation 
for antenatal care of her second pregnancy. Maternal serum screening demonstrat-
ed a very low estriol level of 0.06 multiples of the median (MoM) with low alpha-
fetoprotein (AFP) and human chorionic gonadotropin (hCG) level, 0.6 MoM and 
0.52 MoM, respectively, which were interpreted as a high risk of Edward syndrome Hyun Sun Ko, et al.
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mineralocorticoid, which were tapered to a maintenance dose. 
Therefore, prenatal testing was performed in the second 
sibling for the relevant disease-causing mutation from fetal 
cells by amniocentesis. Exon 7 and its adjacent intronic se-
quences were amplified by PCR, using forward primer 
5’-CCTGGCAGCCTGTTTGTGATAG-3’ and reverse 
primer 5’-ATGAGCGTGTGTACCAGTGCAG-3’, which 
revealed a homozygous c.772C>T substitution resulting in a 
glycine to stop codon substitution at amino acid 258 (Fig. 1). 
A 2,665 g female baby was delivered vaginally with Apgar 
scores of 7 and 9 at 40 weeks’ gestation. At birth, the baby 
presented with normal female external genitalia. Screening 
for congenital adrenal hyperplasia was normal, 17α-OH 
progesterone (17α-OHP) 8.33 ng/mL (normal 1.7-25.0 ng/
mL). There were no clinical signs or symptoms until 3 
months after birth. Four months after birth, the second baby 
was admitted to our hospital with vomiting and diarrhea af-
ter DTaP vaccination. Her laboratory profile was similar to 
that of her sister, but without enlargement of adrenal glands 
on ultrasonography (Table 1). Genetic evaluation from the 
(1 : 79) and Smith-Lemli-Opitz (SLO) syndrome (1 : 7).8,9 
The karyotype by amniocentesis was 46,XX. Level II ultra-
sonography after 21 weeks’ gestation demonstrated no struc-
tural abnormalities including the adrenal glands and genita-
lia. Upon reevaluation of family history, however, the parents 
revealed that their 27-month-old first baby had been diag-
nosed with CLAH. The first baby was delivered vaginally at 
36+2 weeks’ gestation with birth weight 2,360 g. Initial 
symptoms included projectile vomiting and poor oral intake, 
with lethargy and hyperpigmentaion 10 weeks after birth. 
The initial laboratory finding demonstrated hyponatremia 
(125 mEq/L) and hyperkalemia (6.6 mEq/L). Basal adrenal 
hormone levels and an adrenocoticotropic hormone (ACTH) 
stimulation test showed a severe deficiency of adrenal hor-
mones (Table 1). Abdominal ultrasonography and computed 
tomography (CT) demonstrated diffusely enlarged adrenal 
glands with markedly low density. Gene analysis revealed a 
normal CYP21A2 gene sequence but a homozygous muta-
tion c.772C>T in exon 7 of StAR. She was diagnosed with 
CLAH and treated with stress doses of hydrocortisone and 
Table 1. Biochemical Characteristics at Initial Diagnosis
Hormones  Values of the first baby  Values of the second baby Normal ranges 
ACTH   344.77 pg/mL  684.87 pg/mL       10-60 pg/mL
Cortisol       0.53 µg/dL    87.35 µg/dL*         4-19 µg/dL 
Renin     26.93 ng/mL     2.35-37 ng/mL 
Aldosterone       1.45 ng/dL      0.05 ng/mL      1.5-16 ng/dL 
Progesterone             1 ng/dL          <9.2 ng/dL 
Testosterone             1 ng/dL          <3-9 ng/dL 
DHEAS       7.50 µg/dL      88-356 µg/dL 
17-OHP       0.12 ng/mL      0.14 ng/mL     0.1-0.4 ng/mL 
ACTH stimulation test 
    Cortisol  (0 min)       0.53 µg/dL            4-9 µg/dL 
                   (30 min)       0.52 µg/dL 
                   (60 min)       0.52 µg/dL        22-36 µg/dL 
    17-OHP (0 min)       0.12 ng/mL      0.1-0.4 ng/mL 
                   (30 min)       0.13 ng/mL 
                   (60 min)       0.13 ng/mL  0.92-2.34 ng/mL 
ACTH, adrenocoticotropic hormone; DHEAS, dehydroepiandrosterone sulfate; 17-OHP, 17-hydroxyprogesterone caproate.
*This was post hormonal replacement.
Fig. 1. StAR sequencing chromatogram (A: control sample, B: fetus). C to T substitution is expected to produce a glycine to stop codon 
substitution.
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be reevaluated. First, any family history of disordered ste-
roidogenesis should be sought, followed by a detailed pre-
natal ultrasonography looking for the characteristic features 
of SLO syndrome before invasive tests, if required.12 
Due to the difficulty of establishing a diagnosis of CLAH 
from amniotic hormone assays, molecular genetic testing is 
often needed.2,14 It is important that infants born to mothers 
with low estriol levels of unexplained causes should be eval-
uated postnataly, as soon as possible, to rule out adrenal in-
sufficiency. Also, the affected patients should be closely 
monitored in the outpatient clinic, because the majority of 
patients present during the first few months of life with hy-
ponatremia and adrenal crisis.8 
Prenatal molecular genetic diagnosis of CLAH might be 
effective in Korean or Japanese families with the known 
StAR mutations, as well as in families with a 46,XY karyo-
type but female genitalia on ultrasound and/or low maternal 
serum estriol levels, in order to prevent future neonatal 
deaths due to undiagnosed CLAH. Further prospective stud-
ies with larger populations are needed to determine whether 
this would be useful. 
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